



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Peter D. DAVIS

Serial No.: 10/049,248

Group No.: 1626

Filed: May 6, 2002

Examiner.: Rebecca L. Anderson

For: STILBENES WITH VASCULAR DAMAGING ACTIVITY

Attorney Docket No.: U013864-1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION UNDER 37 CFR 1.132

I, Peter David Davis, hereby declare:

1. I am the inventor of the invention described and claimed in US application serial no. 10/049,248 ("the application"). My curriculum vitae is annexed hereto as Exhibit 1.

2. I have had experimentation conducted to test the activity of the compound of Example 2 described at pages 12-13 of the application. The experimentation, which is described below, was conducted under my supervision and I have first hand knowledge of the experimentation and results.

3. Enhanced Activity of Novel VTAs Against CA4P-resistant Tumours

The round-cell sarcoma, SaS, grown as a syngeneic subcutaneous tumour in CBA mice, is highly resistant to combretastatin A4 phosphate (Parkins CS, Holder AL, Hill SA, *et al.*, Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. *Brit J Cancer* 2000; 83: 811-816 and Davis et al. Enhancement of vascular targeting by inhibitors of nitric oxide synthase. *Int J Radiat Oncol Biol Phys.* 2002; 54:1532-6). The following experiments show the surprising activity of the compound of Example 2 (*(Z)*-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate).

4. Induction of Early Necrosis in SaS

The antitumour activity of vascular targeting agents is manifested as an early induction of tumour necrosis. SaS-bearing mice (tumour mean geometric diameter around 6mm) were treated i.p. with combretastatin A4 phosphate, the compound of Example 2 or no drug (controls) and tumors excised 24 h later. After fixation in formalin, sections were made from paraffin-embedded tumors and stained with

hematoxylin and eosin. Sections were scored under the microscope in a blinded fashion according to the following scale: 0-10% necrosis = 1, 11-20% necrosis = 2, and so on until 91-100% necrosis =10. Results are mean scores of sections from at least three tumours. In this assay combretastatin A4 phosphate had little or no activity but the compound of Example 2, even when administered at a lower dose, had marked activity (Table 1).

Table 1. Induction of Necrosis in the SaS tumour


Drug (dose)	Mean Necrosis Score±SEM
Control	1.0 ± 0.0
CA4P (500mg/kg)	1.3 ± 0.2
Compound of Example 2 (300mg/kg)	7.2 ± 0.2

5.1 Growth Delay

Tumor growth was measured following i.p. dose administration. Tumor dimensions were measured in 3 orthogonal diameters using calipers. Five mice were included per treatment group. Growth delay was determined by the time taken to grow to 9 mm (geometric mean diameter, approximately 3mm diameter increase from starting diameter) minus the time for controls to do the same. In this assay combretastatin A4 phosphate (150mg/kg, i.p.) induced growth delay of 0.0 days whereas the compound of Example 2 (150mg/kg, i.p.) induced growth delay of 3.0 days.

6. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity or the application of any patent issued thereon.

Date: 17th August 2004


Peter David Davis



Peter D. Davis
10 Aston Park
Aston Rowant
OXON
OX49 5SW
01865 784660 (W) 01844 351029 (H)
pdd@angiogene.co.uk

E D U C A T I O N

University of Southampton **1974 - 1980**
B.Sc. HONS. CHEMISTRY (1ST CLASS).
PH. D. "STUDIES IN THE SYNTHESIS OF PROSTAGLANDINS".
SUPERVISOR PROF. R. C. COOKSON.

University of California, Irvine **1980 - 1982**
POSTDOCTORAL RESEARCH INTO SYNTHESIS OF TAXANES.

E X P E R I E N C E

Roche Products, UK **1982 - 1991**
TEAM LEADER IN INFLAMMATION GROUP.

Celltech plc, UK **1991-1998**
HEAD OF MEDICINAL CHEMISTRY.

Angiogene Pharmaceuticals Ltd, UK **1998-present**
CHIEF EXECUTIVE OFFICER

P R O F E S S I O N A L Q U A L I F I C A T I O N S

MRSC, C.CHEM

P U B L I C A T I O N S

1. Applications of the Intramolecular Diels-Alder Reaction to the Formation of Strained Molecules.
K. J. Shea, S. Wise, L. D. Burke, P. D. Davis, J. W. Gilman and A. C. Greeley.
J. Am. Chem. Soc. **104**, 5708 (1982).
2. The Tricyclo[9.3.1.0^{3,8}]pentadecane System - a Short Synthesis of a C-aromatic Taxane Skeleton.
K. J. Shea and P. D. Davis.
Angew. Chem. Int. Ed. Engl. **22**, 419 (1983).
3. The Inhibitory Profiles of Hog Pancreatic and Human Rheumatoid Synovial Phospholipase A₂.
J. S. Nixon, S. E. Wilkinson, P.D. Davis and D. P. Bloxham.
Agents and Actions **17**, 299 (1985).
4. Inhibition of Phospholipase A₂ by Some Long-chain Alkylamines.
P. D. Davis, J. S. Nixon, S. E. Wilkinson and M. G. N. Russell.
Biochem. Soc. Trans. **16**, 816 (1988).
5. ¹H-NMR and Protection Studies of Interactions between Ligands and Bovine Pancreatic Phospholipase A₂.
M. P. Williamson, P. D. Davis, M. J. Broadhurst and J. S. Nixon.
Biochimica et Biophysica Acta **997**, 9 (1989).
6. Potent, Selective Inhibitors of Protein Kinase C.
P. D. Davis, C. H. Hill, E. Keech, G. Lawton, J. S. Nixon, A. D. Sedgewick, J. Wadsworth, D. Westmacott and S. E. Wilkinson.
FEBS Letts. **259**, 61 (1989).
7. A Convenient Synthesis of Bisindolyl- and Indolylaryl-Maleic Anhydrides.
P. D. Davis, R. A. Bit and S. A. Hurst.
Tetrahedron Letts. **31**, 5201 (1990).
8. K252a is a Potent and Selective Inhibitor of Phosphorylase Kinase.
L. H. Elliott, S. E. Wilkinson, P. D. Davis, C. H. Hill, G. Lawton, A. D. Sedgewick and J. S. Nixon.
Biochem. Biophys. Res. Commun. **171**, 148 (1990).
9. Modulation of Cellular Processes by H7, a Non-selective Inhibitor of Protein Kinases.
J. S. Nixon, S. E. Wilkinson, P. D. Davis, A. D. Sedgewick, J. Wadsworth and D. Westmacott.
Agents and Actions **32**, 188 (1991).

10. "Protein Kinases" in "*Receptor Data for Biological Experiments*" ed. J. C. van Meel and H. Doods, Ellis Horwood, London, 1991, pp161-168.
11. The Design of Inhibitors of Protein Kinase C; the Solution Conformation of Staurosporine.
P. D. Davis, C. H. Hill, W. A. Thomas and I. W. A. Whitcombe.
J. Chem. Soc. Chem. Commun. 182 (1991).
12. A Dieckmann/Ring Expansion Approach to Tetrahydropyrido- and Tetrahydroazepino-[1,2-a]indoles.
R. A. Bit, P. D. Davis, C. H. Hill, E. Keech and D. R. Vesey.
Tetrahedron 47, 4645 (1991).
13. A Novel Conformationally-restricted Protein Kinase C Inhibitor, Ro 31-8425, Inhibits Human Neutrophil Superoxide Generation by Soluble, Particulate and Post-receptor Stimuli.
R.E. Muid, M Dale, P. D. Davis, L. H. Elliott, C. H. Hill, H. Kumar, G. Lawton, B. M. Twomey, J. Wadsworth, S. E. Wilkinson and J. S. Nixon.
FEBS Letters 293, 169 (1991).
14. Novel, Potent and Selective inhibitors of Protein Kinase C Show Oral Antiinflammatory Activity.
J. S. Nixon, J. Bishop, D. Bradshaw, P. D. Davis, C. H. Hill, L. H. Elliott, H. Kumar, E. J. Lewis, M. Mulqueen, D. Westmacott, J. Wadsworth and S. E. Wilkinson.
Drugs Exp. Clin. Res. 17, 389 (1991).
15. Inhibitors of Protein Kinase C. 1. 2,3-Bisarylmaleimides.
P. D. Davis, C. H. Hill, G. Lawton, J. S. Nixon, S. E. Wilkinson, S. A. Hurst, E. Keech, and S. E. Turner.
J. Med. Chem. 35, 177 (1992).
16. Inhibitors of Protein Kinase C. 2. Substituted Bisindolylmaleimides with Improved Potency and Selectivity.
P. D. Davis, L.H. Elliott, W. Harris, C. H. Hill, S. A. Hurst, E. Keech, M. K. Hari Kumar, G. Lawton, J. S. Nixon and S. E. Wilkinson.
J. Med. Chem. 35, 994 (1992).
17. Oral, Antiinflammatory Activity of a Potent, Selective, Protein Kinase C Inhibitor.
M. J. Mulqueen, D. Bradshaw, P. D. Davis, L. Elliott, T. A. Griffiths, C. H Hill, H. Kumar, G. Lawton, J. S. Nixon, A. D. Sedgewick, J. Wadsworth, D .Westmacott and S. E. Wilkinson.
Agents and Actions 37, 85 (1992).

18. The Design and Biological Properties of Potent and Selective Inhibitors of Protein Kinase C.
J. S. Nixon, J. Bishop, D. Bradshaw, P. D. Davis, C. H. Hill, L. H. Elliott, H. Kumar, G. Lawton, E. J. Lewis, M. Mulqueen, D. Westmacott, J. Wadsworth and S. E. Wilkinson.
Biochem. Soc. Trans. 419 (1992).
19. Inhibitors of Protein Kinase C. 3. Potent and Highly Selective Bisindolylmaleimides by Conformational Restriction.
R. A. Bit, P. D. Davis, L. H. Elliott, W. Harris, C. H. Hill, E. Keech, H. Kumar, G. Lawton, A. Maw, J. S. Nixon, D. R. Vesey, J. Wadsworth and S. E. Wilkinson.
J. Med. Chem. 36, 21 (1993).
20. Bisindolylmaleimide Inhibitors of Protein Kinase C. Further Conformational Restriction of a Tertiary Amine Side Chain.
P. D. Davis, T. J. Hallam, W. Harris, C. H. Hill, G. Lawton, J. S. Nixon, J. L. Smith, D. R. Vesey and S. E. Wilkinson.
Bioorg. Med. Chem. Lett. 4, 1303 (1994).
21. Studies towards the preparation of substituted hydroxyguanidines with tumour specific properties.
A. R. Butler, P. Davis and G. J. Smith
Portland Press Proc. 10 (Biology of Nitric Oxide Part 5), 179 (1996).
22. Inhibition of T-cell Tyrosine Kinases.
P.D.Davis, R. A. Allen, D. A. Berg, J. M. Davis, M. C. Hutchings, R. Martin, D. Moffatt and M. J. Perry in *Medicinal Chemistry Into the Millennium* ed. M. M. Campbell and I. S. Blagborough Royal Society of Chemistry, Cambridge, 2001 pp 174-180.
23. ZD6126: A New Agent Causing Selective Damage Of Tumor Vasculature.
PD Davis, SA Hill, SM Galbraith, DJ Chaplin, MA Naylor, J Nolan and GJ Dougherty
Proc. Amer. Assoc. Cancer Res. 2000, 41: 329.
24. Anti-Tumour Activity Of Vascular Targeting Agent ZD6126 Is Enhanced By Split Dosing.
Davis P.D., Hill S.A., Chaplin D.J. and Dougherty, G. J.
Cancer Res. 2000, 6(Suppl.):99.
25. ZD6126: A New Agent Causing Selective Damage Of Tumour Vasculature
Davis PD, Hill SA, Galbraith SM, Chaplin DJ, Naylor MA, Nolan J and
Dougherty GJ
Brit. J. Cancer 83:P10 (2000).
26. Novel Vascular Targeting Agents: Amino Colchinol Derivatives Of ZD6126.

J. C. Arnould, T. G. Bird, S. E. Ashton, D. C. Blakey and P. D. Davis,
Proc. Amer. Assoc. Cancer Res. 2001, 42: 824.

27. Comparison Of The Anti-Tumor Activity Of Vascular Targeting Agent ZD6126 Administered By Different Routes.

Peter D. Davis, Sally A. Hill, David J. Chaplin, David C. Blakey,
Proc. Amer. Assoc. Cancer Res. 2001, 42: 823.

28. Benzimidazole Carbamates: A New Structural Class Of Vascular Targeting Agents

Peter D. Davis, Peter Thomson, Matthew A. Naylor, John Nolan, Gemma S. Lewis, Sally A. Hill.

Proc. Amer. Assoc. Cancer Res. 42: 371 (2001).

29. Alternative splicing as a novel of means of regulating the expression of therapeutic genes.

Hayes GM, Carpenito C, Davis PD, Dougherty ST, Dirks JF, Dougherty GJ.
Cancer Gene Ther. 133-41 (2002).

30. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ.

Clin. Cancer Res. 8, 1974-83, (2002).

31. Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer.

Carpenito C, Davis PD, Dougherty ST, Dougherty GJ.
In.t J. Radiat. Oncol. Biol. Phys 54 1473-8 (2002).

32. Enhancement of vascular targeting by inhibitors of nitric oxide synthase.

Davis PD, Tozer GM, Naylor MA, Thomson P, Lewis G, Hill SA.

Int. J. Radiat. Oncol. Biol. Phys. 54 1532-6 (2002).

33. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.

Cancer Res. 62 7247-53 (2002).